A carregar...
A Phase 2 Study of Vorinostat for Treatment of Relapsed or Refractory Hodgkin Lymphoma: SWOG S0517
We performed a phase II study of oral vorinostat (200 mg twice daily, days 1–14 of a 21-day cycle), to examine efficacy and tolerability in patients with relapsed/refractory hodgkin lymphoma (HL) with ≤ 5 prior therapies. The primary endpoint was objective response rate (ORR), with secondary endpoin...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3477846/ https://ncbi.nlm.nih.gov/pubmed/21823829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2011.608448 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|